Board and management
Johan Säfholm
M.Sc.
Johan Säfholm graduated with an MSc in Applied Physics from Linköping University in 2003. Since then, he has gained international experience in the development and manufacture of consumer electronics in a variety of roles as team leader and product manager. Johan has worked at Sony Ericsson, ST-Ericsson, Axis and Flatfrog, companies with between 40 and 5,000 employees and a global presence. He also co-founded Swed Ventures AB.
Holds shares in SWIPP.
Christer Sjögren
PhD, Associate Professor
Christer Sjögren is a Doctor of Veterinary Medicine (DVM), has a PhD, and was Associate Professor of pharmacology at The Royal Veterinary College (Kungliga Veterinärhögskolan) until 1975. Christer is also a former consulting professor in experimental obstetrics and gynaecology at Uppsala University. He has more than 45 years’ experience from senior operational management positions at big pharma companies, including Pharmacia and Novo Nordisk, and from similar positions and Board seats at smaller companies, such as Perstorp Pharma, LIDDS AB, Peptonic Medical AB and Juvantia Pharma OY. Christer has also held senior positions at the clinical contract research organisations Quintiles and CDC, has chaired the working group for Clinical Operations and Regulatory Affairs at the industry association SwedenBIO, and has been a board member of VINNOVA’s industry research programme SAMBIO.
Holds shares in SWIPP.
Bengt Westrin
PhD, Associate professor
Bengt Westrin has over 30 years’ experience from the life science industry, ranging from start-ups to big pharma companies, and areas ranging from product development and regulatory affairs to project management and business development.
Prior to SWIPP he was CEO at CombiGene AB, AcuCort AB, Idogen AB and Lipopeptide AB, as well as VP Business Development at Camurus AB. Bengt has also carried out numerous consulting assignments for various companies and public organisations. He has an MSc in Chemical Engineering and a PhD from LTH at Lund University, where he has also been an honorary Associate Professor since 1999. During his time at AcuCort AB, he laid the groundwork for what is now an approved oral film product: Zeqmelit® (dexamethasone) for the treatment of acute allergic reactions, croup, chemotherapy-induced nausea and vomiting, and is also approved for the treatment of Covid-19 patients. Bengt Westrin is named inventor on five patent applications in the film field.
Holds shares in SWIPP.
Bruno Loiseau
MBA
After four years as a strategy consultant at A.T. Kearney, Bruno Loiseau joined Burgundy Ventures Group in 2005 and helped to found AdhexPharma, which subsequently acquired Solvay Pharmaceuticals’ transdermal products. With Bruno as Managing Director, AdhexPharma has seen annual growth of more than 30% since 2007, has registered four new medicinal products as a CDMO, and is currently developing a number of oral films and transdermal patches. AdhexPharma is part of Adhex Group, which has sales in excess of MEUR 130 and approx. 650 employees. Bruno has an MBA from ESSEC Business School and is a French citizen.
Holds shares in SWIPP (through AdhexPharma).